ESR1 and breast cancer: Preliminary results from heavily pre-treated patients with metastatic ER+/HER2− BC showed a favorable safety profile and encouraging anti-tumor activity with an ORR of 12% and a median PFS of 4.3 months (range 3.6–7.1 months).